Mathematical Modeling of T-Cell Mediated Oncolytic Virotherapy for Glioblastoma Treatment
JSHS · 2025
Overview
Oncolytic virotherapy (OV) is a form of immunotherapy that uses specific viruses to prevent cancer cell proliferation. Specifically, the Zika virus has shown promise in combating glioblastoma, and they have shown to work with various aspects of the immune response such as T -Cells to eliminate not only glioblastoma cells, but also cancer stem cells. Mathematical models have also shown promise in simulating how these factors interact with one another. In this paper, we aim to answer the following research que stion: what are the optimal conditions in which the Zika virus population and T -Cell population work together to make the virotherapy as successful as possible? We hypothesized that intermediate values surrounding how efficiently Zika viral particles and T-Cells replenish are necessary for close to successful therapy. Ultimately, by using our ODE (Ordinary Differential Equations) mathematical model, our hypothesis was confirmed; both our analytical and numerical results are in agreement and demonstrate that a lack of either factor is detrimental towards virotherapy. There exists critical values where there are major changes in population dynamics as well as the stability of how the cancer stem cells proliferate or decrease as a result of the Zika virus and/or T-Cells.
Competition history
- JSHS 2025
Resources
Related projects
ISEF · 2019
Using Zika Virus Proteins NS4A and NS4B to Investigate Oncolytic Virus Therapy against Glioblastoma Cancer
ISEF · 2020
Designing a Tumor-Specific Oncolytic Virus to Induce Suicide Gene Expression
ISEF · 2026
GCORE: Glioblastoma-Related Chimeric Antigen Receptor T Cell Therapy Outcome Re-Engineering
ISEF · 2014
Treating GBM BTSCs through Growth Factor Stimulation and Drug-Polymer Conjugate Therapy
ISEF · 2017
Oncolytic Activity of Engineered Adenovirus Ad-TERT in Glioblastoma Multforme
ISEF · 2026
Mathematical Modeling of Enteric Glia-Derived Immune-Metabolic Crosstalk Reveals Synergistic Strategies to Overcome PRDM9- Mediated Ferroptosis Resistance in Glioblastoma
CWSF · 2026
AAV Based Combination Therapies to Improve Glioblastoma Treatment Efficacy
ISEF · 2015
Development of a Novel Oncolytic Virus for Cancer Treatment and Diagnosis
Closest projects by meaning, across every fair and year in the corpus.